James Randi answered your questions. But that was text, and he's a performer ("The Amazing Randi"), so you need to hear the man talk to get his full flavor. He's a good talker, too. So Rob Rozeboom (samzenpus) got on Skype with The Amazing Randi to talk about his exploits, including his debunking of a whole bunch of (alleged) frauds, ranging from Uri Geller to Sylvia Browne. The resulting interview was so long and so strong that we cut it in half. Today you see Part One. Tomorrow you'll see Part Two. (The video's here now; sorry about the delay.)
DEAL: For $25 - Add A Second Phone Number To Your Smartphone for life! Use promo code SLASHDOT25. Also, Slashdot's Facebook page has a chat bot now. Message it for stories and more. Check out the new SourceForge HTML5 internet speed test! ×
astroengine writes "It may not be a lander or an orbiter, but its something. Europa, one of Jupiter's largest moons, has been the focus of much scrutiny over its potential life-bearing qualities. It has an icy crust over a liquid water ocean and now salts have been detected on its surface, suggesting a cycling of nutrients from the surface to the interior. This only amplifies the hypothesis that Europa not only could support basic life, it could support complex life. But how can we find out? The proposed Europa Clipper received interest at NASA HQ last year as it would optimize the science while keeping the mission budget under $2 billion. It would be a spacecraft that will be in orbit around Jupiter, but make multiple flybys of Europa to assess the moon for its habitable qualities. Now, in a bill signed by President Obama and approved by lawmakers, $75 million has been allocated (for the remainder of this fiscal year) for a 'Jupiter Europa mission.' Could it represent the seed money for the Europa Clipper? We'll have to wait and see."
beltsbear writes "Following a reasonable view of drug patents, the Indian courts have decided that making small changes to an existing patented drug are not worthy of a new patent. This ruling makes way for low cost Indian cancer drugs that will save lives. From the Article: 'Novartis lost a six-year legal battle after the court ruled that small changes and improvements to the drug Glivec did not amount to innovation deserving of a patent. The ruling opens the way for generic companies in India to manufacture and sell cheap copies of the drug in the developing world and has implications for HIV and other modern drugs too.'"